Septerna (SEPN)
Develops oral GPCR drug candidates using its Native Complex Platform.
$40.38
After-hours close0.00 (0.00%)
At close$40.38(+4.77%)
Something off on this page? Send us feedback.
13F · 13D/G · Form 4
| Institutions | ≈ 101.18% | 47.23M shares | |
|---|---|---|---|
| 166 holders · as of Jun 30, 2026 · largest filers plus last quarter's tail | |||
| Insiders | 3.09% | 1.44M shares | |
| 8 holders · as of Sep 3, 2026 | |||
| Strategic holders | 13.63% | 6.36M shares | |
| 1 holder · as of Aug 14, 2026 | |||
| Adds to | 117.90% | ||
46.68M company shares as of Sep 23, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
This quarter's institutional total failed a plausibility check; shown: the largest filers plus last quarter's remainder.
These groups come from separate filings that can overlap, so they add to 117.90%; nothing is left for Other.
13F, as of Jun 30, 2026
166 holders · 47.23M shares · 51 new positions · 102 increased · 32 reduced · 17 closed
| Holder | Shares | % outstanding | Chg q/q | Filed |
|---|---|---|---|---|
| Ra Capital Management, L.P. | 7.00M | 14.99% | 0 | Aug 14, 2026 |
| TRV GP V, LLC | 6.22M | 13.32% | 0 | Aug 10, 2026 |
| Driehaus Capital Management LLC | 4.43M | 9.50% | +37.5K | Aug 14, 2026 |
| TRV GP Vi, LLC | 4.21M | 9.02% | 0 | Aug 10, 2026 |
| Samsara Biocapital, LLC | 3.15M | 6.75% | 0 | Aug 14, 2026 |
| Goldman Sachs Group Inc | 3.06M | 6.56% | +156.3K | Aug 14, 2026 |
| BlackRock, Inc. | 1.93M | 4.14% | +109.9K | Aug 7, 2026 |
| Siren, L.L.C. | 1.90M | 4.07% | −100.0K | Aug 13, 2026 |
13D/G · 5% or more, as filed
| Holder | % of class | Shares | Form | Filed |
|---|---|---|---|---|
| Rajeev Shahincl. Peter Kolchinsky, RA Capital Management, L.P. +1 more | 15.80% | 7.00M | 13D | Nov 4, 2024 |
| Third Rock Ventures V, L.P. | 14.00% | 6.22M | 13G | May 9, 2025 |
| Driehaus Capital Management LLC | 10.46% | 4.66M | 13G | Jun 10, 2025 |
| Samsara BioCapital, L.P.incl. Samsara BioCapital GP, LLC, Srinivas Akkaraju | 6.20% | 2.77M | 13G | Nov 4, 2024 |
| BVF Partners L.P.incl. Biotechnology Value Trading Fund OS LP, BVF I GP LLC +7 more | 5.50% | 2.45M | 13G | Nov 1, 2024 |
Form 4
Latest trades
| Date | Insider | Type | Shares | Avg price | Owned after |
|---|---|---|---|---|---|
| Sep 1, 2026 | Daniel D. Longofficer: SVP, Drug Discovery | Sale | 3,333 | $37.83 | 96,412 |
| Aug 12, 2026 | Third Rock Ventures V, L.P.10 percent owner | Sale · 2 lots | 147,200 | $50.27 | 6,068,391 |
| Aug 12, 2026 | Ra Capital Management, L.P.director, 10 percent owner: | Sale | 746,500 | $42.50 | 4,777,415 |
| Aug 11, 2026 | Elizabeth Bhattofficer: President and COO | Sale | 25,000 | $44.00 | 174,209 |
| Aug 3, 2026 | Daniel D. Longofficer: SVP, Drug Discovery | Sale · 2 lots | 3,334 | $34.47 | 96,412 |
| Jul 15, 2026 | Elizabeth Bhattofficer: President and COO | Sale | 4,000 | $33.99 | 174,209 |
| Jul 1, 2026 | Daniel D. Longofficer: SVP, Drug Discovery | Sale · 2 lots | 3,333 | $34.36 | 96,412 |
| Jun 29, 2026 | Samira Shaikhlyofficer: Chief People Officer | Sale | 2,178 | $35.18 | 793 |
| Jun 22, 2026 | Daniel D. Longofficer: SVP, Drug Discovery | Sale · 2 lots | 15,000 | $35.51 | 96,412 |
| Jun 12, 2026 | Samira Shaikhlyofficer: Chief People Officer | Sale | 6,250 | $35.08 | 793 |
House and Senate disclosures
Not reported.